Skip to main content
. 2020 Dec 8;324(22):2282–2291. doi: 10.1001/jama.2020.22960

Figure 2. Primary End Point in a Study of the Effect of Co-trimoxazole vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Idiopathic Pulmonary Fibrosis.

Figure 2.

Kaplan-Meier estimates for time to event for the primary end point (death [all causes], lung transplant, or first nonelective hospital admission), analyzed according to the group to which participants were randomized. There was no significant difference between the co-trimoxazole and placebo groups. Median (interquartile range) follow-up was 12.0 (4.4-21.0) months.